Recent approvals of TRK inhibitors have demonstrated the success of a tumor agnostic approach to oncogene-targeted therapy across cancers. Collective data from acquired resistance studies suggest that resistance mechanisms, which include both kinase domain mutations and bypass signaling via RTK-RAS-RAF-MAPK pathways, frequently recur regardless of tumor type, oncogene, and drug.

中文翻译：

---

获得性耐药是癌基因和药物不可知的。

TRK抑制剂的最新批准证明了肿瘤不可知论方法成功用于跨癌症的癌基因靶向治疗。来自获得性抗药性研究的集体数据表明，无论肿瘤类型，致癌基因和药物如何，抗药性机制（包括激酶结构域突变和通过RTK-RAS-RAF-MAPK途径的旁路信号转导）都经常复发。